- Home
- JBTM vs NUVL Comparison
JBTM vs NUVL Comparison
Compare JBTM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBTM
- NUVL
- Stock Information
- Founded
- JBTM 1994
- NUVL 2017
- Country
- JBTM United States
- NUVL United States
- Employees
- JBTM N/A
- NUVL N/A
- Industry
- JBTM
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- JBTM
- NUVL Health Care
- Exchange
- JBTM Nasdaq
- NUVL Nasdaq
- Market Cap
- JBTM 7.3B
- NUVL 7.1B
- IPO Year
- JBTM N/A
- NUVL 2021
- Fundamental
- Price
- JBTM $135.02
- NUVL $96.89
- Analyst Decision
- JBTM Strong Buy
- NUVL Strong Buy
- Analyst Count
- JBTM 2
- NUVL 13
- Target Price
- JBTM $143.00
- NUVL $123.54
- AVG Volume (30 Days)
- JBTM 554.3K
- NUVL 552.4K
- Earning Date
- JBTM 11-03-2025
- NUVL 10-30-2025
- Dividend Yield
- JBTM 0.30%
- NUVL N/A
- EPS Growth
- JBTM N/A
- NUVL N/A
- EPS
- JBTM N/A
- NUVL N/A
- Revenue
- JBTM $3,257,800,000.00
- NUVL N/A
- Revenue This Year
- JBTM $120.28
- NUVL N/A
- Revenue Next Year
- JBTM $4.84
- NUVL N/A
- P/E Ratio
- JBTM N/A
- NUVL N/A
- Revenue Growth
- JBTM 92.43
- NUVL N/A
- 52 Week Low
- JBTM $90.08
- NUVL $55.54
- 52 Week High
- JBTM $148.77
- NUVL $104.90
- Technical
- Relative Strength Index (RSI)
- JBTM 47.71
- NUVL 55.68
- Support Level
- JBTM $135.86
- NUVL $90.99
- Resistance Level
- JBTM $144.85
- NUVL $99.12
- Average True Range (ATR)
- JBTM 4.30
- NUVL 4.79
- MACD
- JBTM 0.80
- NUVL -0.47
- Stochastic Oscillator
- JBTM 54.85
- NUVL 45.94
About JBTM JBT Marel Corporation
JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.